Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0158)
Name
Ferric citrate
Synonyms
FERRIC CITRATE; Iron(III) citrate; Iron citrate; Zerenex; 3522-50-7; 6043-74-9; 28633-45-6; ferrum citricum; Citric acid, iron(3+) salt; FERRICCITRATE; Iron(III) citrate tribasic; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt (1:1); ferric citrate anhydrous; KRX-0502; iron(iii)citrate; Iron citrate, FeC6H5O7; Auryxia; iron(3+) citrate; 63G354M39Z; Iron, (hydrogen citrato(3-))-; 2338-05-8; Citric acid, iron(3+) salt (1:1); FERROUS CITRATE; iron(III) 2-hydroxypropane-1,2,3-tricarboxylate; 2-hydroxy-1,2,3-propanetricarboxylic acid iron salt; Ferric citrate [USAN]; Ferric citrate tetrahydrate; Iron(III) citrate; Zerenex; JTT-751; Ferric citrate (VAN); 2-hydroxypropane-1,2,3-tricarboxylate;iron(3+); NSC-112227; Fexeric; iron(3+) 2-hydroxypropane-1,2,3-tricarboxylate; UNII-63G354M39Z; JTT 751; EINECS 222-536-6; EINECS 249-117-0; Iron(III)-citrate; Iron (III) citrate; NSC 112227; Citric acid, iron salt; 1185-57-5; Citric acid,iron(3+)salt; FERRIC CITRATE [MI]; SCHEMBL42945; FERRIC CITRATE [FCC]; 2-hydroxypropane-1,2,3-tricarboxylate; iron(3+); FERRIC CITRATE [INCI]; FERRUM CITRICUM [HPUS]; CCRIS 6843; DTXSID0037657; FERRIC CITRATE [WHO-DD]; Iron(III) citrate;Iron citrate; HY-N1428C; NPFOYSMITVOQOS-UHFFFAOYSA-K; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt; BCP30645; FERRIC CITRATE [ORANGE BOOK]; AKOS015918266; DB09162; CS-0030977; FT-0626407; FT-0627304; FT-0652224; Iron 2-hydroxy-1,2,3-propanetricarboxylate; A832727; iron(3+); 2-oxidanylpropane-1,2,3-tricarboxylate; Q15628111; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron salt (1:?)

    Click to Show/Hide
Structure
3D MOL
2D MOL
Formula
C6H5FeO7
IUPAC Name
2-hydroxypropane-1,2,3-tricarboxylate;iron(3+)
Canonical SMILES
C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Fe+3]
InChI
InChI=1S/C6H8O7.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3
InChIKey
NPFOYSMITVOQOS-UHFFFAOYSA-K
PubChem CID
61300
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Sarcopenia ICD-11: FB32
 Disease Info 
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Glutathione metabolism hsa00480
Cell Process Cell ferroptosis
In Vitro Model C2C12 cells Normal Mus musculus CVCL_0188
In Vivo Model
The 8-week- and 40-week-old male SAMP8 mice were purchased from the model animal research center of Zhishan Institute of Healthcare Research Co., Ltd. (Beijing, China). All the mice were kept in an SPF grade animal facility at 24 with a relative humidity of 50%-60%, and in a light/dark cycle of 12 h/12 h.

    Click to Show/Hide
Response regulation Ferric citrate induced ferroptosis in C2C12 cells, as well as impaired their differentiation from myoblasts to myotubes. Iron overload upregulated the expression of P53, which subsequently repressed the protein level of Slc7a11 (solute carrier family 7, member 11), a known ferroptosis-related gene. Targeting iron accumulation and ferroptosis might be a therapeutic strategy for treating sarcopenia.
References
Ref 1 Ferroptosis in a sarcopenia model of senescence accelerated mouse prone 8 (SAMP8). Int J Biol Sci. 2021 Jan 1;17(1):151-162. doi: 10.7150/ijbs.53126. eCollection 2021.